Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease

Vaccine

Volumn 31, Issue 46, 2013, Pages 5306-5313

  Janssen, Robert S ^a   Mangoo Karim, Roberto ^b   Pergola, Pablo E ^c   Girndt, Matthias ^d   Namini, Hamid ^a   Rahman, Sophia ^a   Bennett, Sean R ^a   Heyward, William L ^a   Martin, J Tyler ^a  

^a Dynavax Technologies Corporation   (United States)

^b Gamma Clinical Research   (United States)

^c Renal Associates   (United States)

^d MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

Hepatitis B vaccine; Randomized trial; Toll like receptor 9

Indexed keywords

ALUMINUM POTASSIUM SULFATE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B SURFACE ANTIGEN 1018; IMMUNOLOGICAL ADJUVANT; RECOMBINANT HEPATITIS B VACCINE; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HEMODIALYSIS; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; VACCINATION;

HEPATITIS B VACCINE; RANDOMIZED TRIAL; TOLL-LIKE RECEPTOR 9;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; MALE; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; RENAL INSUFFICIENCY, CHRONIC; SINGLE-BLIND METHOD; TOLL-LIKE RECEPTOR 9; VACCINATION; YOUNG ADULT;

EID: 84886101528     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.05.067     Document Type: Article

References (27)

1. Centers for Disease Control and Prevention Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001, 50(RR-5):1-43.
2. Previsani N., Lavanchy D., Zuckerman A.J., Hepatitis B. Viral hepatitis: molecular biology, diagnosis, epidemiology and control. 2004, 31-98. Elsevier, Amsterdam. I.K. Mushahwar (Ed.).
3. Miller E.R., Alter M.J., Tokars J.I. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis 1999, 33(2):356-360.
4. Assad S., Francis A. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine 1999, 18(1-2):57-67.
5. DaRoza G., Loewen A., Djurdjev O., Love J., Kempston C., Burnett S., et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis 2003, 42(6):1184-1192.
6. Keating G.M., Noble S. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003, 63(10):1021-1051.
7. McNulty C.A., Bowen J.K., Williams A.J. Hepatitis B vaccination in predialysis chronic renal failure patients a comparison of two vaccination schedules. Vaccine 2005, 23(32):4142-4147.
8. Douvin C., Simon D., Charles M.A., Deforges L., Bierling P., Lehner V., et al. Hepatitis B vaccination in diabetic patients. Randomized trial comparing recombinant vaccines containing and not containing pre-S2 antigen. Diabetes Care 1997, 20(2):148-151.
9. Johnson D.W., Fleming S.J. The use of vaccines in renal failure. Clin Pharmacokinet 1992, 22(6):434-446.
10. Tong N.K., Beran J., Kee S.A., Miguel J.L., Sánchez C., Bayas J.M., et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005, 68(5):2298-2303.
11. Fraser G.M., Ochana N., Fenyves D., Neumann L., Chazan R., Niv Y., et al. Increasing serum creatinine and age reduce the response to hepatitis B vaccine in renal failure patients. J Hepatol 1994, 21(3):450-454.
12. Girndt M., Litjens N.H. Unmet needs and new promises in hepatitis B vaccination for chronic kidney disease patients. Eur Nephrol 2010, 4:14-18.
13. Mast E.E., Weinbaum C.M., Fiore A.E., Alter M.J., Bell B.P., Finelli L., et al. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States - Recommendations of the Advisory Committee on Immunization Practices (ACIP), Part II: immunization of adults. MMWR Morb Mortal Wkly Rep 2006, 55(RR-16):1-33.
14. Hadler S.C., Francis D.P., Maynard J.E., Thompson S.E., Judson F.N., Echenberg D.F., et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986, 315(4):209-214.
15. McMahon B.J., Dentinger C.M., Bruden D., Zanis C., Peters H., Hurlburt D., et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009, 200(9):1390-1396.
16. Buti M., Viladomiu L., Jardi R., Olmos A., Rodriguez J.A., Bartolome J., et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol 1992, 12(3):144-147.
17. Jilg W., Lorbeer B., Schmidt M., Wilske B., Zoulek G., Deinhardt F. Clinical evaluation of a recombinant hepatitis B vaccine. Lancet 1984, 2(8413):1174-1175.
18. Floreani A., Baldo V., Cristofoletti M., Renzulli G., Valeri A., Zanetti C., et al. Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. Vaccine 2004, 22(5-6):607-610.
19. Chaves S.S., Daniels D., Cooper B.W., Malo-Schlegel S., Macarthur S., Robbins K.C., et al. Immunogenicity of hepatitis B vaccine among hemodialysis patients: effect of revaccination of non-responders and duration of protection. Vaccine 2011, 29(52):9618-9623.
20. Sezer S., Ozdemir F.N., Güz G., Arat Z., Colak T., Sengul S., et al. Factors influencing response to hepatitis B virus vaccination in hemodialysis patients. Transplant Proc 2000 May, 32(3):607-608.
21. Navarro J.F., Teruel J.L., Mateos M.L., Marcen R., Ortuno J. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol 1996, 16(2):95-97.
22. Standing Committee on Vaccination at the Robert Koch Institute Recommendations of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute/Effective: July 2012. Epidemiol Bull 2012, 30:283-302.
23. Heyward W.L., Kyle M., Blumenau J., Davis M., Reisinger K., Kabongo M.L., et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age. Vaccine 2013, 31(46):5300-5305.
24. ® (Hepatitis B vaccine [recombinant]) prescribing information 2012.
25. Newcombe R.G. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998, 17(8):873-890.
26. Clopper C.J., Pearson E.S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934, 26:404-413.
27. Institute of Medicine Adverse effects of vaccines: evidence and causality 2012, The National Academies Press, Washington, DC.